Sufang Chu

1.2k total citations
28 papers, 739 citations indexed

About

Sufang Chu is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sufang Chu has authored 28 papers receiving a total of 739 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 16 papers in Cancer Research and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sufang Chu's work include RNA modifications and cancer (10 papers), Cancer-related molecular mechanisms research (8 papers) and Epigenetics and DNA Methylation (7 papers). Sufang Chu is often cited by papers focused on RNA modifications and cancer (10 papers), Cancer-related molecular mechanisms research (8 papers) and Epigenetics and DNA Methylation (7 papers). Sufang Chu collaborates with scholars based in China, United Kingdom and Taiwan. Sufang Chu's co-authors include Jin Bai, Pingfu Hou, Junnian Zheng, Zhongwei Li, Minle Li, Xintian Chen, Sen Meng, Hongmei Yong, Tian Lin and Yuming Gu and has published in prestigious journals such as Oncogene, British Journal of Cancer and Frontiers in Immunology.

In The Last Decade

Sufang Chu

27 papers receiving 733 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sufang Chu China 13 626 396 90 80 76 28 739
Huanye Mo China 16 404 0.6× 350 0.9× 76 0.8× 47 0.6× 108 1.4× 24 561
Hee Doo Yang South Korea 13 479 0.8× 279 0.7× 80 0.9× 42 0.5× 61 0.8× 18 607
Yizhi Zhan China 13 411 0.7× 241 0.6× 131 1.5× 126 1.6× 84 1.1× 18 621
Xuechao Wan China 17 737 1.2× 571 1.4× 69 0.8× 44 0.6× 153 2.0× 27 902
Ge Lou China 14 473 0.8× 225 0.6× 111 1.2× 66 0.8× 30 0.4× 27 595
Chun-Cai Gu China 13 635 1.0× 479 1.2× 155 1.7× 74 0.9× 90 1.2× 17 846
Mingyi Shang China 13 536 0.9× 425 1.1× 135 1.5× 120 1.5× 86 1.1× 22 735
Yaliang Lan China 9 360 0.6× 296 0.7× 77 0.9× 57 0.7× 55 0.7× 12 526

Countries citing papers authored by Sufang Chu

Since Specialization
Citations

This map shows the geographic impact of Sufang Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sufang Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sufang Chu more than expected).

Fields of papers citing papers by Sufang Chu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sufang Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sufang Chu. The network helps show where Sufang Chu may publish in the future.

Co-authorship network of co-authors of Sufang Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Sufang Chu. A scholar is included among the top collaborators of Sufang Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sufang Chu. Sufang Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shao, Zhiying, Xintian Chen, Tingting Tang, et al.. (2025). TRIM21-mediated PRMT1 degradation attenuates colorectal cancer malignant progression. Cell Death and Disease. 16(1). 56–56. 3 indexed citations
2.
Yang, Wendong, Zhiheng Zhang, Mingming Zhao, et al.. (2025). P300-dependent acetylation of the FOXQ1 complex activates super-enhancers to promote colorectal cancer proliferation and metastasis. Communications Biology. 8(1). 1016–1016. 1 indexed citations
3.
Liu, Yiwei, Ke Shao, Qi Shen, et al.. (2024). Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma. Cell Death and Disease. 15(6). 395–395. 6 indexed citations
4.
5.
Shen, Zhigang, Tao Dong, Hongmei Yong, et al.. (2024). FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation. Cell Death Discovery. 10(1). 151–151. 4 indexed citations
6.
Wang, Yan, Chunjie Wu, Pingfu Hou, et al.. (2024). circEPB41L2 blocks the progression and metastasis in non-small cell lung cancer by promoting TRIP12-triggered PTBP1 ubiquitylation. Cell Death Discovery. 10(1). 72–72. 7 indexed citations
7.
Shi, Lei, et al.. (2023). FBXO22 inhibits proliferation and metastasis of cervical cancer cells by mediating ubiquitination-dependent degradation of GAK. Experimental Cell Research. 430(1). 113719–113719. 3 indexed citations
8.
Shao, Zhiying, Xiannan Meng, Minle Li, et al.. (2023). The role of transcription factor Yin Yang‐1 in colorectal cancer. Cancer Medicine. 12(10). 11177–11190. 8 indexed citations
9.
Li, Zhongwei, Hongmei Yong, Lei Jiang, et al.. (2023). PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression. Cell Death and Disease. 14(5). 322–322. 22 indexed citations
10.
Chen, Xintian, Hongmei Yong, Pengfei Wang, et al.. (2023). TRIM21 attenuates renal carcinoma lipogenesis and malignancy by regulating SREBF1 protein stability. Journal of Experimental & Clinical Cancer Research. 42(1). 34–34. 25 indexed citations
11.
Yong, Hongmei, Sufang Chu, Minle Li, et al.. (2022). Long noncoding RNA SH3PXD2A-AS1 promotes NSCLC proliferation and accelerates cell cycle progression by interacting with DHX9. Cell Death Discovery. 8(1). 192–192. 9 indexed citations
12.
Zhang, Hui, et al.. (2022). KIF4A drives gliomas growth by transcriptional repression of Rac1/Cdc42 to induce cytoskeletal remodeling in glioma cells. Journal of Cancer. 13(15). 3640–3651. 11 indexed citations
13.
Li, Minle, Xue Zhao, Hongmei Yong, et al.. (2022). Transketolase promotes colorectal cancer metastasis through regulating AKT phosphorylation. Cell Death and Disease. 13(2). 99–99. 37 indexed citations
14.
Li, Zhongwei, Haiyuan Yu, Pengfei Wang, et al.. (2022). DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability. Oncogene. 41(33). 3991–4002. 37 indexed citations
15.
Hou, Pingfu, Sen Meng, Minle Li, et al.. (2021). LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification. Journal of Experimental & Clinical Cancer Research. 40(1). 365–365. 161 indexed citations
16.
Li, Zhongwei, Diandian Wang, Xintian Chen, et al.. (2021). PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. Cell Death and Disease. 12(11). 1080–1080. 42 indexed citations
17.
Chen, Xintian, Zhongwei Li, Hongmei Yong, et al.. (2021). Trim21-mediated HIF-1α degradation attenuates aerobic glycolysis to inhibit renal cancer tumorigenesis and metastasis. Cancer Letters. 508. 115–126. 58 indexed citations
18.
Hou, Pingfu, Tian Lin, Sen Meng, et al.. (2021). Long noncoding RNA SH3PXD2A-AS1 promotes colorectal cancer progression by regulating p53-mediated gene transcription. International Journal of Biological Sciences. 17(8). 1979–1994. 10 indexed citations
19.
Liu, Guihong, Liantao Li, Tao Jiang, et al.. (2020). The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma. Investigational New Drugs. 38(6). 1730–1742. 10 indexed citations
20.
Hou, Pingfu, Hailong Li, Hongmei Yong, et al.. (2019). PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway. Angiogenesis. 22(4). 507–519. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Huanye Mo Breakdown of academic impact, for papers by Hee Doo Yang Breakdown of academic impact, for papers by Yizhi Zhan Breakdown of academic impact, for papers by Xuechao Wan Breakdown of academic impact, for papers by Ge Lou Breakdown of academic impact, for papers by Chun-Cai Gu Breakdown of academic impact, for papers by Mingyi Shang Breakdown of academic impact, for papers by Yaliang Lan
Rankless by CCL
2026